Ranibizumab and photodynamic therapy successful

Article

A ranibizumab and photodynamic therapy combination can improve visual acuity and reduce exudation in polypoidal choroidal vasculopathy.

A ranibizumab and photodynamic therapy combination can improve visual acuity and reduce exudation in polypoidal choroidal vasculopathy.

Dr Masaaki Saito et al., Department of Ophthalmology, Fukushima Medical University School of Medicine, Fukushima, Japan, retrospectively reviewed 28 eyes of 28 patients with visual acuity of 20/40 or less. Each patient was treated with three consecutive monthly injections of ranibizumab and underwent photodynamic therapy on day one or two after the injections.

Mean best-corrected vicual acuity (BCVA) improved from 0.33 at baseline to 0/61 at the 12-month follow-up. The mean improvement in BCVA at 12 months from baseline was 2.65 lines.

Central retinal thickness was significantly reduced from 366 µm to 151 µm at 12 months and there were no complications. The combined therapy can be used to maintain or improve visual acuity in polypodal choroidal vasculopathy, as well as reduce exudation without adverse events.

The abstract appeared in the latest edition of the journal Retina.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.